Important Disclaimer: The information in this blog article is for educational purposes only and should not be considered medical advice
You might not be thrilled by everything you read, but its definitely worth your time.
Similar content being viewed by others Introduction Animals rely on well-developed nervous systems to dexterously take prompt movements and rapidly facilitate long-range information exchange in front of the changing environment
For type 2 diabetes management , NICE guideline NG28 recommends GLP-1 receptor agonists as a treatment option when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI of 35 kg/m or higher (or lower thresholds for people from South Asian and related minority ethnic backgrounds) Weight loss would benefit other obesity-related comorbidities Continuation of GLP-1 therapy for diabetes typically requires demonstration of beneficial response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months
Furthermore, he continued, they produce 15 to 20 percent weight loss, which is mediated by many circuits in the brain
Because GLP-1 drugs improve those underlying factors, scientists are asking: could these drugs also protect the brain
